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Purpose: To retrospectively evaluate the effect of post-prostate-biopsy hemorrhage on 
the interpretation of magnetic resonance diffusion-weighted (MRDW) and magnetic 
resonance spectroscopic (MRS) imaging in the detection of prostate cancer. We also in-
vestigated the optimal timing for magnetic resonance examination after prostate 
biopsy.
Materials and Methods: We reviewed the records of 135 men. All patients underwent 
prostate magnetic resonance imaging (MRI). The prostate was divided into eight re-
gions according to the biopsy site. Subsequently, we measured hemorrhage on apparent 
diffusion coefficient (ADC) values and (choline+creatinine)/citrate ([Cho+Cr]/Cit) ra-
tios in the same regions on the MRI. We investigated the effect of hemorrhage at ADC 
values and (Cho+Cr)/Cit ratios on MRI and the relationship between prostate biopsy 
results and MRI findings.
Results: The mean patient age was 68.7 years and the mean time between biopsy and 
MRI was 23.5 days. The total hemorrhagic score demonstrated no significant associa-
tions with intervals from biopsy to MRI. Higher hemorrhagic scores were associated 
with higher ADC values, prostate cancer, and noncancer groups, respectively (p
＜0.001). ADC values were lower in tumors than in normal tissue (p＜0.001), and ADC 
values were inversely correlated with tumor Gleason score in biopsy cores (p＜0.001). 
However, (Cho+Cr)/Cit ratios did not exhibit any association with prostate biopsy re-
sults and hemorrhage.
Conclusions: Hemorrhage had no significant associations with the interval from biopsy 
to MRI. ADC values may help to detect prostate cancer and predict the aggressiveness 
of cancer; however, it is important to consider the bias effect of hemorrhage on the inter-
pretation of MRDW imaging given that hemorrhage affects ADC values.
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scopy; Prostatic neoplasms
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 30 May, 2011
accepted 2 August, 2011
Corresponding Author:
In Ho Chang
Department of Urology, Chung-Ang 
University Hospital, 224-1, 
Heukseok-dong, Dongjak-gu, Seoul 
156-755, Korea
TEL: +82-2-6299-1819
FAX: +82-2-6294-1406
E-mail: caucih@cau.ac.kr
This research was supported by the 
Chung-Ang University research 
grants in 2011, Republic of Korea.
INTRODUCTION
Prostate cancer is the most frequent malignancy of the 
male genitourinary tract, with an incidence in Asians of ap-
proximately 82.2 cases per 100,000 [1]. Early detection of 
prostate cancer has been essential for decreasing mortality 
rates. As a result of widespread screening with the pros-
tate-specific antigen (PSA), prostate cancer has been in-
creasingly detected at an early stage [2]; however, the spe-
cificity of the PSA level for prostate cancer screening has 
been limited, and even at PSA levels between 2.5 and 4 
ng/ml, cancer is detected in only 25% to 30% of biopsies [3]. 
A noninvasive test that could detect or exclude such areas 
throughout the prostate would be of great diagnostic help 
in prostate cancer patients. Thus, magnetic resonance 
imaging (MRI) has become increasingly important in the 
local staging of prostate cancer. 
　Despite its promise, however, accurate MRI has been Korean J Urol 2011;52:674-680
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complicated by interference from conditions other than 
prostate cancer, including hemorrhage after biopsy, radio-
therapy and hormone therapy, scars, positional and in-
flammatory changes, and dystrophic changes [4]. Among 
these factors, hemorrhaging after biopsy has been the most 
common obstacle to the accurate detection of prostate can-
cer after a prostate biopsy. Therefore, despite the useful-
ness of MRI, it can be influenced by post-biopsy hemor-
rhage. For that reason, magnetic resonance diffusion-wei-
ghted (MRDW) and magnetic resonance spectroscopic 
(MRS) imaging have been adopted as useful tools to over-
come the weaknesses of MRI. Prostate magnetic resonance 
and MRS imaging together with the evaluation of metabo-
lites such as choline, creatine, and citrate have shown con-
siderable promise in the evaluation of tumor diagnosis, ex-
tent, and aggressiveness in patients with biopsy-proven 
prostate cancer [5-8]. A number of studies have found high 
choline levels and low citrate levels in the areas affected 
by prostate carcinoma. Therefore, it was reported that the 
(choline+creatinine)/citrate ([Cho+Cr]/Cit) level may be 
an effective indicator of prostate cancer [9-11].
　Furthermore, MRDW now makes it possible to obtain 
images of the movement of water molecules in organs. The 
diffusion properties of the examined tissue can be quanti-
fied by calculating the diffusion coefficient, termed the ap-
parent diffusion coefficient (ADC). Studies on prostate can-
cers have suggested that an increase in ADC values, caused 
by the loss of cellular density, can provide an early quanti-
tative assessment of a positive tumor response [12]. 
　For the aforementioned reasons, MRDW and MRS have 
been helpful in the differential diagnosis of prostate cancer. 
However, the usefulness of MRDW and MRS tests for 
post-biopsy hemorrhage has yet to be studied. Therefore, 
in this study we evaluated the effect of post-prostate biopsy 
hemorrhage on the interpretation of MRDW and MRS 
imaging in the detection of prostate cancer. Also, we also 
investigated the hemorrhagic effects on MRI according to 
the interval from biopsy to MRI to find the optimal timing 
for MR examination after prostate biopsy.
MATERIALS AND METHODS
1. Patients
This retrospective study was approved by our institutional 
review board. We reviewed the records of 135 men in whom 
prostate cancer had been detected following prostate 
biopsy. All patients underwent MRI (T1-weighted, 
T2-weighted, diffusion-weighted [DW] imaging, and MRS 
examinations) after ultrasonographic-guided systematic 
prostate biopsy of more than 8 cores from January 2007 and 
March 2011 at our institution. We performed additional bi-
opsies on hypoechoic lesions found on prostate ultrasono-
graphy. Among the participants, five men were excluded 
from this study because they did not match one or more of 
the following inclusion criteria: MRI examination includ-
ing DW and MRS imaging and prostate biopsy results 
available for review. MRI was performed from 1 to less than 
61 days after prostate biopsy and no treatment for prostate 
cancer was received before MRI.
　In all subjects, a tissue diagnosis of prostate cancer was 
determined from an analysis of prostate biopsy specimens. 
Patient age, PSA level, prostate volume, biopsy results for 
Gleason score, and percentage of tumor involvement of the 
biopsy core were recorded from a review of the patients’ 
medical and pathologic records. 
2. Magnetic resonance imaging examination
All prostate MRI examinations were performed on a 3.0-T 
system (Intera Achieva 3.0T, Philips Medical Systems, 
Best, The Netherlands). Sequences acquired included 
thin-section high-spatial-resolution sagittal, axial, and co-
ronal T2-weighted fast spin-echo (FSE) images of the pros-
tate and seminal vesicle with the following parameters: TR 
3300-3800 ms, TE 80-100 ms, slice thickness 3.0 mm, gap 
0.3 mm, and 512x360 matrix. Our protocol also included 
T1-weighted FSE sequences (TR 2300-3000 ms, TE 63-65 
ms, slice thickness 3.0 mm, gap 1 mm, 80x80 matrix) to de-
tect post-biopsy prostate hemorrhage. Diffusion-encoding 
gradients were applied as bipolar pairs at b-values of 0 and 
1000 s/mm
2 along the axial directions of motion-probing 
gradients. 
3. Magnetic resonance imaging analysis and histopatho-
logic findings
For visual assessment, hemorrhage was considered to be 
present when an area of high signal intensity within the 
prostate was observed on T1-weighted MRI. T2-weighted 
images were used in distinguishing between transitional 
and peripheral zones. The prostate peripheral zone was 
divided into 8 sectors, which were divided in the same way 
as the prostate biopsy region (Fig. 1).
Regions of interest (ROIs) were drawn manually by re-
viewing the uroradiologist’s T1-weighted MRI ADC maps 
in each of the 8 sectors. The ROI area range was 10.19 mm
2. 
Mean signal intensity values and SDs in the ROI were auto-
matically determined by using picture archiving and com-
munication system (PACS), and the ADC maps were auto-
matically constructed pixel-by-pixel and ADC values for 
each ROI were generated by using PACS. ADC maps ob-
tained by using a b-value of 1000 s/mm
2 were assessed (Fig. 
1).
　Uroradiologists graded the degree of visible post-biopsy 
hemorrhage in each of the 8 sectors by using a 4-point scale: 
a score of 0 indicated no hemorrhage; 1, hemorrhage involv-
ing ＜1/3 of a sector; 2, hemorrhage involving 1/3 to 2/3 of 
a sector; and 3, hemorrhage involving ＞2/3 of a sector. For 
each patient, the total score calculated by summing up the 
hemorrhage scores from all 8 sectors was designated as the 
total hemorrhage score [13,14]. 
　Three-dimensional MRS imaging data were acquired by 
using a water and lipid-suppressed double spin-echo 
point-resolved spectroscopy (PRESS) sequence. After ex-
amination, one experienced uroradiologist, blinded to pa-
tient status, performed a consensus review of all MRI, and Korean J Urol 2011;52:674-680
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FIG. 1. (A) A schematic illustration demonstrating the peripheral zone of the prostate divided into eight sectors on the magnetic 
resonance imaging (MRI). (B) Transverse T1-weighted MRI obtained at 3 weeks after prostate biopsy demonstrating a post-biopsy 
hemorrhage score of three (arrow) as a high signal intensity area in the prostate peripheral zone. (C) Apparent diffusion coefficient 
value (0.88x10
−3 mm
2/s) showing low diffusivity in the right peripheral zone (star). (D) Fusion imaging of MRI and magnetic 
resonance spectroscopic imaging and related (choline+creatinine)/citrate ([Cho+Cr]/Cit) ratio.
TABLE 1. Patient characteristics
Value
Total no. of patients 135
Age (yr) 68.7±8.9
Prostate volume (cc) 39.4±17.6
PSA 43.1±200.4
Interval from biopsy to MRI  23.5±12.4
Hemorrhage score 
     0 597 (55.3)
     1 204 (18.9)
     2 173 (16.0)
     3 106 (9.8)
Gleason score at biopsy 
     3+3 203 (39.3)
     3+4   90 (17.4)
     4+3 114 (22.1)
     4+4 104 (20.2)
     5+4   15 (2.9)
Values are presented as mean±SD or number (%), PSA: pros-
tate-specific antigen, MRI: magnetic resonance imaging
calculated (Cho+Cr)/Cit levels. In each reading session, 
high-resolution T2-weighted imaging was used seconda-
rily if descriptions of anatomic details of the prostate were 
needed (Fig. 1). Pathology slides were reviewed retro-
spectively by a pathologist and Gleason scores were cal-
culated.
4. Statistical analysis
We retrospectively analyzed the pathologic data regarding 
biopsy, including age, weight, serum PSA level at diag-
nosis, prostate volume, biopsy Gleason score, and the inter-
val from biopsy to MRI. We used Spearman correlation 
analysis to measure the correlation between total hemor-
rhage score and the interval from biopsy to MRI. We inves-
tigated the effect of hemorrhage score (0-3) on ADC values 
and (Cho+Cr)/Cit ratio, and the relationship between pros-
tate biopsy results and MRI findings by Student's t-test, 
ANOVA, and chi-square test using SPSS ver. 17.0 (SPSS 
Inc., Chicago, IL, USA). A level of significance of 5% was 
adopted.
RESULTS
Patient demographic outcomes are provided in Table 1. In Korean J Urol 2011;52:674-680
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FIG. 2. Total hemorrhage score on magnetic resonance imaging 
(MRI) according to the interval from biopsy to MRI (p=0.133).
TABLE 2.  Comparison of ADC values and (Cho+Cr)/Cit ratios in prostate cancer tissue and noncancer tissue at each prostate sector
Number (%) ADC (±SD) 10
−3 mm
2/s p-value (Cho+Cr)/Cit (±SD) p-value
Hemorrhage score
     0 594 55.0  ±1.28 0.3 ＜0.001 11.79 ±115.5 0.718
     1 206 19.1  ±1.32 0.27 5.91 ±19.42
     2 174 16.1  ±1.39 0.29 4.47 ±15.53
     3 106 9.8  ±1.5 0.28 4.09 ±10.67
Hemorrhage score of prostate cancer tissue
     0 316 61.2  ±1.2 0.29 ＜0.001 16.7 ±158.56 0.804
     1 94 18.2  ±1.25 0.29 6.08 ±14.31
     2 67 13.0  ±1.36 0.29 2.21 ±4.03
     3 39 7.6  ±1.47 0.27 4.25 ±13.03
Hemorrhage score of noncancer tissue
     0 278 49.2  ±1.36 0.29 ＜0.001 6.4 ±15.73 0.832
     1 112 19.9  ±1.38 0.23 5.76 ±23.32
     2 107 19.0  ±1.41 0.3 5.93 ±18.3
     3 67 11.9  ±1.52 0.28 4 ±9.27
Cancer tissue vs noncancer tissue
    Non-cancer 564 52.2  ±1.39 0.28 ＜0.001 5.9 ±17.26 0.31
    Cancer 516 47.8  ±1.25 0.3 11.88 ±123.86
ADC: apparent diffusion coefficient, (Cho+Cr)/Cit: (choline+creatinine)/citrate ratio 
FIG. 3. Scatterplot showing the relationship between apparent 
diffusion coefficient (ADC) values in a diffusion-weighted image 
and tumor Gleason score. ADC values were inversely correlated 
with tumor Gleason score in biopsy cores (p＜0.001).
this study, 135 men (mean age, 68.7 years; range, 38 to 91 
years) had a total of 1080 core prostate biopsies, and 516 
(47.8%) of these biopsies yielded prostate cancer. The mean 
PSA level was 43.1 (range, 1.18 to 1384) (Table 1).
The mean interval from TRUS-guided biopsy to MRI was 
23.5 days (range, 1 to 61 days), and the mean total hemor-
rhage score for our subjects was 6.3 (range, 0 to 23) as grad-
ed from prostate MRI. Total hemorrhage scores demon-
strated no significant correlations with the interval from 
biopsy to MRI (p=0.133)(Fig. 2), ADC values and cancer, 
or the effect of prostate biopsy hemorrhage on MRDW or 
MRS imaging.
The mean ADC (SD) score was significantly lower for seg-
ments with cancer, at 1.25 (0.30)x10
−3 mm
2/s, than for seg-
ments without cancer, at 1.39 (0.28)x10
−3  mm
2/s (p＜ 
0.001). Higher hemorrhagic scores indicated a significant 
association with higher ADC values for all scores (0 to 3) 
in both prostate cancer and non-prostate-cancer groups. In 
the cancer group, 1.2 (0.29)x10
−3 mm
2/s represented a 
hemorrhage score of 0, 1.25 (0.29)x10
−3 mm
2/s a hemor-
rhage score of 1, 1.36 (0.29)x10
−3 mm
2/s a hemorrhage score 
of 2, and 1.47 (0.27)x10
−3 mm
2/s a hemorrhage score of 3. 
In the noncancer group, 1.36 (0.29)x10
−3 mm
2/s repre-
sented a hemorrhage score of 0, 1.38 (0.23)x10
−3 mm
2/s a 
hemorrhage score of 1, 1.41 (0.3)x10
−3 mm
2/s a hemorrhage 
score of 2, and 1.52 (0.28)x10
−3 mm
2/s a hemorrhage score 
of 3 (p＜0.001)(Table 2). Furthermore, ADC values were in-
versely correlated with tumor Gleason scores in biopsy 
cores (p＜0.001)(Fig. 3).
Table 2 shows the relationship between the (Cho+Cr)/Cit 
ratio and hemorrhagic grade in cancer and noncancer, re-Korean J Urol 2011;52:674-680
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spectively (p＞0.718, p＞0.804). Also, the (Cho+Cr)/Cit ra-
tio did not show any association with prostate biopsy re-
sults (p＞0.832). 
DISCUSSION
Accurate tumor staging is necessary to determine the ex-
tent of disease and the choice of treatment. In general, pros-
tate cancer commonly has a lower signal intensity than the 
normal peripheral zone of the prostate on T2 MRI [15]. 
More recently, other authors found that the standardized 
T2 signal intensity of prostate tumors was related to the 
tumor's Gleason score and lower signal intensities were 
found in higher tumor grades [16]. The role of MRI in pros-
tate cancer has been the local staging of disease and diag-
nosis of extracapsular tumor extension [17]. Also, new 
treatment strategies (e.g., imaging-guided brachyther-
apy, laser therapy, and cryotherapy) have required an ex-
tension of diagnostic imaging beyond staging to provide 
more precise information about tumor presence and loca-
tion [18-20]. MRI has demonstrated good sensitivity but 
low specificity in identifying tumor location because of a 
large number of false-positives (e.g., cancer, hemorrhage 
after biopsy, change after radiotherapy, inflammatory 
changes, and scars) [4]. Accurate tumor localization will al-
low greater benefit of treatment to areas of prostate cancer 
and will ideally increase the effectiveness of treatment 
while reducing treatment-related morbidity.
　Prostate cancer is diagnosed in patients through a pros-
tate biopsy. Accordingly, hemorrhage is major barrier to 
achieving accurate MRI interpretation, and the reduction 
of any hemorrhage effects is necessary to minimize this 
barrier. As such, patients undergoing anticoagulant ther-
apy should have that stopped 5 to 7 days before prostate 
biopsy, warfarin should not be taken, and the international 
normalized ratio needs to be corrected to ＜1.5 [21]. 
　Several studies have reported a relationship between di-
minished time of hemorrhage grade and the time from biop-
sy [22,23], with some authors arguing that hemorrhage 
was significantly reduced up to 21days after prostate biop-
sy [5]. Other authors have suggested that MRI and MRS 
imaging should be conducted 8 weeks after biopsy [23]; 
however, other authors have argued that hemorrhage was 
not significantly reduced until 55 days after prostate biop-
sy [13]. In our study, 137 men were examined, and the mean 
time between biopsy and MRI was 23.5 days. The total hem-
orrhagic score from eight cores demonstrated no sig-
nificant associations with the interval from biopsy to MRI 
(p=0.133). Our observation that total hemorrhage grade 
was not correlated with the time between biopsy and MRI 
may indicate that the after effects of prostate biopsy may 
last for variable time periods in different patients. 
Therefore, we do not recommend individualized deferred 
MRI times for more accurate cancer staging.
　ADCs for prostate cancer detection have been signifi-
cantly lower in cancer tissue than in noncancerous tissue 
[24,25]; however, some authors have demonstrated a wide 
variability of ADC values in noncancerous tissue, which 
causes a considerable overlap of ADC values between can-
cerous and noncancerous tissue [26]. For that reason, we 
investigated the following two areas: the correlation of 
ADC values and cancer, and the effect of a hemorrhage on 
ADC values. In our study, the mean ADC (SD) score was 
significantly lower for segments with cancer, at 1.25 (0.30), 
than for segments without cancer, at 1.39 (0.28) (p＜0.001). 
Diffusion-weighted imaging is based on differences in wa-
ter molecule diffusion that are attributable to differences 
in cellular density between normal and cancerous prostate 
tissue. We wanted to examine the association between the 
hemorrhage and MRI of the prostate. For that reason, we 
had to calculate ADC values even though hemorrhage had 
an effect on detecting prostate cancer. In our study, a higher 
hemorrhagic score meant a significant association with 
higher ADC values at all scores (0 to 3) in both prostate can-
cer and non-prostate-cancer groups. We extrapolated that 
these results were due to the effects of hemorrhage on the 
relaxation properties of prostate tissues and on contrast 
enhancement (representing microvessel density and leaky 
vasculature).
　We also investigated the relationship between the ADC 
values and the aggressiveness of prostate cancer. In our 
study, ADC values were inversely correlated with tumor 
Gleason score in biopsy cores (p＜0.001). That meant that 
the degree of prostate cancer differentiation influenced the 
signal intensity of this tumor on DW imaging. The lower 
ADC values in the more aggressive tumors in our study may 
have been due to higher cellular density in poorly differ-
entiated tumors, resulting in more restricted movement of 
water protons [27]. Therefore, it was demonstrated that 
ADC values could aid in the understanding of cancer 
aggressiveness. 
In several studies, MRI has had good specificity but low 
sensitivity in the detection of prostate cancer [4-7]. 
Kozlowski et al reported that combining DW with dynamic 
imaging obtained better sensitivity, with a small decrease 
in specificity in the differentiation between cancer and non-
cancer lesions [28]. In a recent study, combined MR and 
MRS imaging were better with respect to diagnostic per-
formance than MRI alone [29,30]. Furthermore, a number 
of studies have found high choline levels and low citrate lev-
els in prostate cancer [9,10]; however, we found no correla-
tion between the (Cho+Cr)/Cit ratio and hemorrhage grade 
and no significant differences in (Cho+Cr)/Cit ratios be-
tween cancer and noncancer lesions. We hypothesized that 
these findings were due to two reasons. First, there were 
some differences in protocol between hospitals. The stand-
ardization of imaging is very important in order to accu-
rately measure (Cho+Cr)/Cit ratios; however, we did not 
have a standardized protocol and it was therefore difficult 
to validate the (Cho+Cr)/Cit ratio levels. Second, the (Cho+ 
Cr)/Cit ratio is a highly sensitive exam and is biased by any 
patient movement. In our hospital, MRS required more 
than 20 minutes, and we believe that the (Cho+Cr)/Cit ra-
tios may have been biased by patient movement [31]. Korean J Urol 2011;52:674-680
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There were limitations to the present study. First, this 
study involved relatively few patients from a single in-
stitute, and the study was retrospective. We need further 
studies including those in a multicenter manner using vali-
dated MRS protocols as well as prospective studies. 
Second, this study was retrospective, and even if the most 
similar MRI and pathology sections had been selected, 
there was still some inconsistency between pathology and 
radiology sections. It is very important to ensure con-
sistency between pathologic and MRI regions to accurately 
measure ADC and (Cho+Cr)/Cit ratios. In the current 
study, we did not validate this consistency, and we used 
ROI to measure on MRI imaging; however, ROI on MRI was 
not consistent with the core size of prostate biopsies. The 
third limitation was that hyperintensity on DW images has 
been reported in hyperacute (intracellular oxy Hb) and late 
subacute (extracellular meth Hb) stages of hemorrhage. 
The ADC values have been reported to be decreased in the 
hyperacute stage and increased in the late subacute stage 
[32,33]. In the current study, we did not examine ADC and 
hemorrhage across the five periods (hyperacute, acute, 
early subacute, late subacute, and chronic state); however, 
the hemorrhage score was associated with ADC values and 
it is important to consider the bias effect of hemorrhage on 
the interpretation of MRDW imaging given that hemor-
rhage can affect ADC values. The last limitation was that 
we used biopsy specimens instead of prostatectomy 
specimens. Discrepancies exist between prostate biopsy 
and prostatectomy specimens; therefore, we will inves-
tigate the correlation between MRDW and MRS findings 
and prostatectomy specimens in future studies. Despite 
these limitations, the current study is the first to inves-
tigate the effect of hemorrhage on MRDW and MRS find-
ings in normal prostate and prostate cancer specimens. In 
the future, more accurate imaging markers on MRI that are 
unaffected by hemorrhage will aid in the diagnosis of pros-
tate cancer. 
CONCLUSIONS
Hemorrhage had no significant associations with the inter-
val from biopsy to MRI. Furthermore, ADC values may help 
to detect prostate cancer and predict the aggressiveness of 
cancer; however, it is important to consider the bias effect 
of hemorrhage on the interpretation of MRDW imaging giv-
en that hemorrhage can affect ADC values.
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